Advertisement
Screener

TRAVERE THERAPEUTICS, INC. (TVTX) Exchange Rate Effect on Cash

2.8 / 5 stars · 68/120 Roast Me

TRAVERE THERAPEUTICS, INC. Exchange Rate Effect on Cash

TRAVERE THERAPEUTICS, INC. (TVTX) reported Exchange Rate Effect on Cash of -$135.00 thousand for the 12-month period ending 2018-12-31, per its 10-K filed 2019-02-26.

Discontinued › Cash Flow › Change in Cash

us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents · last filed 2019-02-26

  • TRAVERE THERAPEUTICS, INC. effect of exchange rate on cash and cash equivalents for the quarter ending 2018-03-31 was $10.00K, a 150.00% increase year-over-year.
  • TRAVERE THERAPEUTICS, INC. effect of exchange rate on cash and cash equivalents for the quarter ending 2017-03-31 was $4.00K.
  • TRAVERE THERAPEUTICS, INC. effect of exchange rate on cash and cash equivalents for the quarter ending 2016-03-31 was -$294.00K.
  • TRAVERE THERAPEUTICS, INC. effect of exchange rate on cash and cash equivalents for the quarter ending 2015-03-31 was $0.00.
  • TRAVERE THERAPEUTICS, INC. effect of exchange rate on cash and cash equivalents for fiscal 2018 was -$135.00K.
  • TRAVERE THERAPEUTICS, INC. effect of exchange rate on cash and cash equivalents for fiscal 2017 was -$58.00K, a 149.57% decline from fiscal 2016.
  • TRAVERE THERAPEUTICS, INC. effect of exchange rate on cash and cash equivalents for fiscal 2016 was $117.00K.
  • TRAVERE THERAPEUTICS, INC. effect of exchange rate on cash and cash equivalents for fiscal 2015 was -$10.00K.
Period endEffect of Exchange Rate on Cash and Cash Equivalents 3 monthEffect of Exchange Rate on Cash and Cash Equivalents 3 month as first filedEffect of Exchange Rate on Cash and Cash Equivalents 6 monthEffect of Exchange Rate on Cash and Cash Equivalents 6 month as first filedEffect of Exchange Rate on Cash and Cash Equivalents 9 monthEffect of Exchange Rate on Cash and Cash Equivalents 12 month
2018-12-31-$135.00K
10-K · filed 2019-02-26
2018-09-30-$30.00K
10-Q · filed 2018-11-01
2018-06-30-$34.00K
10-Q · filed 2018-08-03
2018-03-31$10.00K
10-Q · filed 2018-07-06
2017-12-31-$58.00K
10-K · filed 2019-02-26
2017-09-30-$57.00K
10-Q · filed 2018-11-01
2017-06-30$63.00K
10-Q · filed 2018-08-03
-$497.00K
10-Q · filed 2017-08-09
2017-03-31$4.00K
10-Q · filed 2018-07-06
-$119.00K
10-Q · filed 2017-05-05
2016-12-31$117.00K
10-K · filed 2019-02-26
2016-09-30-$57.00K
10-Q · filed 2017-11-07
2016-06-30-$182.00K
10-Q · filed 2017-08-09
2016-03-31-$294.00K
10-Q · filed 2017-05-05
2015-12-31-$10.00K
10-K · filed 2018-07-06
2015-09-30$0.00
10-Q · filed 2016-11-04
2015-06-30$0.00
10-Q · filed 2016-08-05
2015-03-31$0.00
10-Q · filed 2016-05-05
2014-12-31$0.00
10-K · filed 2017-03-01
2013-12-31$0.00
10-K · filed 2016-02-26

Similar stocks

Stock NameCountryMarket CapPE Ratio
Oruka Therapeutics, Inc. (ORKA)United States$5.663B-43.76
Mirum Pharmaceuticals, Inc. (MIRM)United States$5.798B-8.81
Cogent Biosciences, Inc. (COGT)United States$5.450B-17.61
Gossamer Bio, Inc. (GOSS)United States$5.355B-0.65
PTC THERAPEUTICS, INC. (PTCT)United States$5.199B-177.07
Amneal Pharmaceuticals, Inc. (AMRX)$6.326B25.62
Dianthus Therapeutics, Inc. /DE/ (DNTH)United States$5.082B-27.79
Liquidia Corp (LQDA)United States$6.347B51.23
Erasca, Inc. (ERAS)United States$5.073B-19.96
Veradermics, Inc (MANE)United States$4.839B